TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
53,852
|
37,319
|
25,265 |
| Financial expenses |
4,171
|
5,005
|
1,976 |
| Earnings before taxes |
8,518
|
2,005
|
652 |
| EBITDA |
5,777
|
4,365
|
-729 |
| Total assets |
197,874
|
155,737
|
150,837 |
| Current assets |
74,478
|
42,011
|
53,538 |
| Current liabilities |
12,120
|
12,122
|
10,220 |
| Equity capital |
175,292
|
128,513
|
125,693 |
| - share capital |
73
|
68
|
74 |
| Employees (average) |
130
|
114
|
92 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
88.6%
|
82.5%
|
83.3% |
| Turnover per employee |
414
|
327
|
275 |
| Profit as a percentage of turnover |
15.8%
|
5.4%
|
2.6% |
| Return on assets (ROA) |
6.4%
|
4.5%
|
1.7% |
| Current ratio |
614.5%
|
346.6%
|
523.9% |
| Return on equity (ROE) |
4.9%
|
1.6%
|
0.5% |
| Change turnover |
16,425
|
14,100
|
7,678 |
| Change turnover % |
44%
|
61%
|
44% |
| Chg. No. of employees |
16
|
22
|
29 |
| Chg. No. of employees % |
14%
|
24%
|
46% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.